title: [A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy].
abstract: We report a case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy. A 59-year-old man presented with anal pain. A colonoscopy revealed primary rectal cancer. The histological diagnosis was well to moderately differentiated adenocarcinoma. A computed tomography showed metastases to pararectal, both inguinal lymph nodes and right external iliac. After a ileostomy construction was done, he was treated with intensity modulated radiotherapy (a total 50.4 Gy) and chemotherapy with FOLFOX. The primary tumor had completely disappeared, and metastases to lymph nodes showed a remarkable shrinkage after the chemoradiotherapy. Nine months after radiation therapy, however, multiple lung and liver metastases were observed by a computed tomography, which were treated by systemic chemotherapy with FOLFOX and bevacizumab. The primary tumor and metastases to lymph nodes are still controlled well for 2 years after the initial chemoradiotherapy.
authors.affiliation: Dept. of Surgery, NTT West Osaka Hospital.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kanoh
authors.forename: Tadashi
authors.initials: T
authors.lastname: Ohnishi
authors.forename: Katsuki
authors.initials: K
authors.lastname: Danno
authors.forename: Ami
authors.initials: A
authors.lastname: Watanabe
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Nakamura
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Tsukao
authors.forename: Junichi
authors.initials: J
authors.lastname: Inatome
authors.forename: Chiwan
authors.initials: C
authors.lastname: Kim
authors.forename: Naofumi
authors.initials: N
authors.lastname: Kagara
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kimura
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tono
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Nakano
authors.forename: Takushi
authors.initials: T
authors.lastname: Monden
authors.forename: Shingi
authors.initials: S
authors.lastname: Imaoka
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007081:Ileostomy; D007264:Inguinal Canal; D002955:Leucovorin / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D050397:Radiotherapy, Intensity-Modulated; D012004:Rectal Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil